

Resource Summary Report

Generated by SPARC SAWG on Aug 26, 2026

PE anti-human IgG Fc

RRID:AB_10900424

Type: Antibody

Proper Citation

BioLegend Cat# 409303, RRID:AB_10900424

Antibody Information

URL: http://antibodyregistry.org/AB_10900424

Proper Citation: BioLegend Cat# 409303, RRID:AB_10900424

Target Antigen: IgG

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued; Applications: FC

Antibody Name: PE anti-human IgG Fc

Description: This monoclonal targets IgG

Target Organism: Human, Rabbit, Cross-Reactivity: Goat, Horse, Sheep

Clone ID: Clone HP6017

Antibody ID: AB_10900424

Vendor: BioLegend

Catalog Number: 409303

Alternative Catalog Numbers: 409304

Record Creation Time: 20250820T020458+0000

Record Last Update: 20250820T123845+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human IgG Fc.

Warning: Discontinued at BioLegend
Discontinued; Applications: FC

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Duhan V, et al. (2025) FcR?-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity. Cancer immunology research, 13(12), 2075.

Camargo CP, et al. (2024) Single-cell adhesive profiling in an optofluidic device elucidates CD8+ T lymphocyte phenotypes in inflamed vasculature-like microenvironments. Cell reports methods, 4(4), 100743.

Fukushima Y, et al. (2022) cis interaction of CD153 with TCR/CD3 is crucial for the pathogenic activation of senescence-associated T cells. Cell reports, 40(12), 111373.

Jeong D, et al. (2021) Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2. eLife, 10.

Park JA, et al. (2021) Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. Journal for immunotherapy of cancer, 9(5).

Hamdan F, et al. (2021) Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. Journal for immunotherapy of cancer, 9(8).

Park JA, et al. (2020) GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. Journal of hematology & oncology, 13(1), 172.

Takeda A, et al. (2019) Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils. Immunity, 51(3), 561.